Keyword: Momenta Pharmaceuticals
Pfizer CEO Ian Read hands over reins; Nimbus promotes CFO Keiper to CEO spot; and Synlogic names Brennan as permanent CEO.
Momenta is axing 50% of its workforce as it drops the bulk of its biosimilar work in favor of an immunology-based novel pipeline.
Details on Westphal's new venture are sketchy, with a corporate filing saying the company is "developing immunotherapy treatments for cancer."
Here's a FierceBiotech Radio episode about the Battle of the Biotech Bands, ahead of the podcast's relaunch in 2018.
Lilly's longtime CFO Rice will retire, Akari's CEO resigned amid a false data scandal, MannKind replaced its CEO with the hope to revive Afrezza.
Momenta was up nearly 6% after hours last night when it unveiled a new research deal with CSL Limited for its Fc multimer proteins, months after flopping in a phase 2 cancer test.
Shire has returned rights to the two biosimilars that Baxalta had in development.
Momenta has stopped a Phase II pancreatic cancer trial of necuparanib after an interim futility analysis found a lack of efficacy.